Such activation releases IFN-I, chemokines CXCL10 and CCL5, and cytokines interleukin-15 (IL-15)/IL-15R and IL-18, thereby allowing crosstalk of NK cells and dendritic cells for reprogramming of macrophages for an improved therapeutic outcome in melanoma patients. This evidence concerns the gene IL15 and melanoma.